Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial.

Randomized, double-blind, placebo-controlled, crossover trial in 50 healthy adult smokers aged 20-50 years without major chronic disease. The resveratrol-first arm had 25 participants randomized and 24 analyzed; the placebo-first arm had 25 participants randomized and 25 analyzed.

Transmax resveratrol 500 mg was taken orally as one tablet each morning after an overnight fast for 30 days. In the crossover design, participants received resveratrol and placebo in separate 30-day periods with a washout between periods.

Resveratrol showed a favorable anti-inflammatory and antioxidant effect in healthy smokers. Compared with placebo, end-of-resveratrol values were lower for CRP, with an adjusted ratio of 0.47 (95% CI 0.38-0.59), and triglycerides, with an adjusted ratio of 0.71 (95% CI 0.65-0.78). Total antioxidant status increased by 74.2 mol/L (95% CI 60.8-87.6), and no adverse events were reported. The findings suggest resveratrol may help reduce cardiovascular risk markers in this population.

The trial was small and short, with only 30 days of active supplementation per period and one dropout in the resveratrol-first arm. Generalizability is limited to healthy smokers, and sex distribution, detailed baseline characteristics, and ethnic composition were not reported. Cross-over interpretation is also constrained by the brief washout and the limited number of outcomes reported.